Humacyte (HUMA) Long-Term Investments (2020 - 2021)

Humacyte (HUMA) reported Long-Term Investments of $100.0 million for Q2 2021, little changed quarter-over-quarter from $100.0 million in Q1 2021.

Humacyte (HUMA) Long-Term Investments (2020 - 2021) Analysis & Trends

Humacyte (HUMA) has 2 years of Long-Term Investments data on file, last reported at $100.0 million in Q2 2021.

Long-Term Investments for Q2 2021 came in at $100.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $100.0 million (changed N/A YoY), and the FY2020 annual result was $100.0 million, changed N/A from the prior year.
Long-Term Investments steadied at $100.0 million in Q2 2021 per HUMA's latest filing, from $100.0 million in the prior quarter.
Over five years, Long-Term Investments peaked at $100.0 million in Q2 2021 and troughed at $100.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	5.75 Bn
9	Abivax	94.26 Bn	94.26 Bn	-	-
10	Humacyte	267.09 Mn	218.55 Mn	-1.54 Mn	-

Download Data